Cargando…

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis

BACKGROUND: Tissue released blood-based biomarkers can provide insight into drug mode of action and response. To understand the changes in extracellular matrix turnover, we analyzed biomarkers associated with joint tissue turnover from a phase 3, randomized, placebo-controlled study of baricitinib i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thudium, Christian S., Bay-Jensen, Anne C., Cahya, Suntara, Dow, Ernst R., Karsdal, Morten A., Koch, Alisa E., Zhang, Wenling, Benschop, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552555/ https://www.ncbi.nlm.nih.gov/pubmed/33046136 http://dx.doi.org/10.1186/s13075-020-02340-7

Ejemplares similares

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study
por: Bay-Jensen, Anne C., et al.
Publicado: (2016)

Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis
por: Kjelgaard‐Petersen, Cecilie F., et al.
Publicado: (2018)

The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatment
por: Kalogera, Stefania, et al.
Publicado: (2021)

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2019)

Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
por: Praveen, D., et al.
Publicado: (2020)

Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19
por: Finsterer, Josef, et al.
Publicado: (2021)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Dynamic compression inhibits cytokine-mediated type II collagen degradation
por: Engstrøm, Amalie, et al.
Publicado: (2022)

The Janus kinase inhibitor (baricitinib) suppresses the rheumatoid arthritis active marker gliostatin/thymidine phosphorylase in human fibroblast-like synoviocytes
por: Joyo, Yuji, et al.
Publicado: (2022)

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
por: Kubo, Satoshi, et al.
Publicado: (2018)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
por: Sonia, Chiging, et al.
Publicado: (2022)

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2022)

Blood and urine biomarkers in osteoarthritis – an update on cartilage associated type II collagen and aggrecan markers
por: Bay-Jensen, Anne C., et al.
Publicado: (2022)

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
por: Mayence, Annie, et al.
Publicado: (2019)

Incidence of total hip and total knee replacements from the prospective epidemiologic risk factor study: considerations for event driven clinical trial design
por: Bager, Cecilie L., et al.
Publicado: (2019)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter, Max, et al.
Publicado: (2019)

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
por: Li, SiNi, et al.
Publicado: (2021)

Pathological tissue formation and degradation biomarkers correlate with patient reported pain outcomes: an explorative study
por: Bay-Jensen, Anne C., et al.
Publicado: (2023)

Baricitinib exposure during pregnancy in rheumatoid arthritis
por: Costanzo, Giulia, et al.
Publicado: (2020)

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
por: Emery, Paul, et al.
Publicado: (2021)

Osteoclasts degrade bone and cartilage knee joint compartments through different resorption processes
por: Löfvall, Henrik, et al.
Publicado: (2018)

Role of LIGHT in the pathogenesis of joint destruction in rheumatoid arthritis
por: Sabokbar, Afsie, et al.
Publicado: (2017)

Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities
por: Karsdal, Morten A, et al.
Publicado: (2011)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

A Highly Sensitive Biomarker of Type II Collagen C-Terminal Pro-Peptide Associated with Cartilage Formation
por: Port, Helena, et al.
Publicado: (2022)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Gene therapy in rheumatoid arthritis: how to target joint destruction?
por: Pap, Thomas, et al.
Publicado: (1999)

Relevance of Biomarkers in Serum vs. Synovial Fluid in Patients with Knee Osteoarthritis
por: Kalogera, Stefania, et al.
Publicado: (2023)

Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)
por: Montealegre, G, et al.
Publicado: (2015)

Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway
por: Dang, Chun, et al.
Publicado: (2021)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
por: Kawalec, Paweł, et al.
Publicado: (2019)

Are There Any Ethnic Differences in the Response to Baricitinib for the Treatment of Rheumatoid Arthritis?
por: Zahir Hussain, Wajith Hussain, et al.
Publicado: (2021)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study
por: Drobinski, Patryk J., et al.
Publicado: (2021)

Fibroblasts are not just fibroblasts: clear differences between dermal and pulmonary fibroblasts’ response to fibrotic growth factors
por: Madsen, Sofie Falkenløve, et al.
Publicado: (2023)

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
por: Titanji, Boghuma K, et al.
Publicado: (2020)

NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_63j7a6rp54jrifeofvsfl87od2